Bio Protocol Raises $6.9 Million to Enhance AI-Driven Biotech Research
- Bio Protocol secured $6.9 million in funding from investors including Maelstrom Fund and Animoca Brands.
- The platform aims to revolutionize drug discovery by integrating AI, blockchain technology, and community involvement.
- Decentralized AI agents, known as “BioAgents,” will facilitate hypothesis generation and funding for experiments.
- Each research step will be recorded on-chain to ensure transparency and credit for contributors.
- The project is part of the broader DeSci movement aimed at improving scientific research accessibility and efficiency.
Bio Protocol’s innovative approach seeks to address inefficiencies in academic research by reducing reliance on traditional funding sources like universities and pharmaceutical companies. By utilizing decentralized governance and crypto incentives, it aims to create a more collaborative research environment.
With $6.9 million raised, Bio Protocol is positioned to significantly impact the biotech landscape through its AI-native framework for decentralized science.(Source)
